After each conference this blog links to a series of education-related information on important findings related to ongoing challenges of managing and treating viral hepatitis. Listed below are programs reviewing key HCV data presented at the International Liver Congress™, with links to additional coverage.
Although the following video/lecture program is aimed at clinicians, it's pretty cut and dry; easy to comprehend. In addition Viral Ed will be launching an expert review of the meeting on May 1, 2017.
This page will be updated as new learning activities become available, with a dated reminder on the sidebar of this blog.
Hepatitis C - 5-minutes videos each day from The International Liver Congress™ available at Practice Point Hepatitis
In this video series, Dr. Tran will present "what you need to know in 5 minutes" offering us a quick review of clinical studies on new antiviral therapy, data on drug toxicity/adverse events, drug interactions, and strategies for HCV management.
Free registration is required to view videos, sign up here...
After you register scroll down before clicking on "Access Video"
Main Menu
Click here to view videos each day from The International Liver Congress™ (ILC) 2017, 52nd annual meeting of the European Association for the Study of the Liver (EASL).
*This conference coverage is not sanctioned by the conference organizers (European Association for the Study of the Liver) and is not an official part of the conference proceedings from ILC 2017.
Video Highlights
Day One
Expedition-1 Glecaprevir/Pibrentasvir HCV Genotypes 1,2,4,5,6 and compensated cirrhosis
HCC reoccurrence after interferon-free therapy
Day Two
Endurance 3 Glecaprevir/Pibrentasvir treatment naïve genotype 3 without cirrhosis
HBV/HCV Coinfected - Ledipasvir/Sofosbuvir 12weeks
Real-World Observational Study in the U.S. Veterans Affairs System Evaluating Use of Merck’s (Elbasvir and Grazoprevir)
German Registry - SVR 12 rates with interferon-free therapies in advanced HCV-associated cirrhosis
Direct-acting antiviral treatment in children
Day Three
Magellan-1 Part 2: Glecaprevir/Pibrentasvir HCV Genotype 1 or 4 Prior DAA Failures
Magellan-2 Glecaprevir/Pibrentasvir in liver or renal transplant recipients with HCV genotype 1-6
Coming Soon
May 1 over @ Viral Ed
The Advances in Chronic Hepatitis C: Management and Treatment program is a comprehensive, expert review of the 52nd Annual Meeting of the European Association for the Study of the Liver (EASL 2017). This program will feature HCV experts reviewing and discussing the most important studies on chronic hepatitis C presented at EASL 2017. This review and discussion will provide a comprehensive overview of each of the posters and presentations as selected by our faculty panel. In addition, the faculty will provide unique insights into how knowledgeable experts review and analyze data from EASL and an in-depth understanding of the scientific quality and clinical relevance of the posters and presentations reviewed. May 1 over @ Viral Ed
Begin here......
ViralEd - Daily Highlights from EASL 2017
Helpful Links
International Liver Congress™ 2017
Updates On This Blog
Slides available @ NATAP
Meeting Updates & Videos
Healio
Meeting Updates
Medpage Today
Videos
Liver Cancer
Oncology Conference Multimedia
OncLive
Abstract Book
Journal Of Hepatology
EASL YouTube Channel
Published on April 20
ILC 2017 - Press conference 1
HCV Post SVR Management and Complications
EASL In The Press
Press Room
Coverage
Hep
Of Interest
Published on Apr 20
Raquel Peck, CEO World Hepatitis Alliance, speaks at opening ceremony at EASL's International Liver Congress April 2017. She casts the wide vision of worldwide hepatitis elimination, and challenges medical professionals to be partners in the effort. And she shares a bit of her own amazing story.
HCV Resource Links
HCV Resource Links
No comments:
Post a Comment